Agilent/Dako

Prostate Specific Antigen Membrane Antigen

#M3620 · immunohistochemistry

34
Citing papers
1.5k
Combined citations
Supplier page Find this product

Research areas

Prostate Cancer Treatment and Research32Radiopharmaceutical Chemistry and Applications19Prostate Cancer Diagnosis and Treatment12Peptidase Inhibition and Analysis6Immunotherapy and Immune Responses4Ubiquitin and proteasome pathways3Glioma Diagnosis and Treatment3Urologic and reproductive health conditions3

Papers citing this product

1
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors
The Journal of Experimental Medicine·2017·193 cit.·DOI
2
Immunohistochemical Validation of PSMA Expression Measured by <sup>68</sup>Ga-PSMA PET/CT in Primary Prostate Cancer
Journal of Nuclear Medicine·2017·161 cit.·DOI
3
Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy
EJNMMI Research·2015·150 cit.·DOI
4
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
Clinical Cancer Research·2019·121 cit.·DOI
5
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
Nature Communications·2023·118 cit.·DOI
6
Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer
Oncotarget·2016·103 cit.·DOI
7
First Clinicopathologic Evidence of a Non–PSMA-Related Uptake Mechanism for <sup>68</sup>Ga-PSMA-11 in Salivary Glands
Journal of Nuclear Medicine·2019·97 cit.·DOI
8
<sup>123</sup>I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy
Journal of Nuclear Medicine·2011·82 cit.·DOI
9
MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer
Nature Communications·2021·73 cit.·DOI
10
Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging·2021·56 cit.·DOI

Rate this reagent

Used this in your lab? Leave a quick rating. Reviews are anonymous and verified by academic email before they appear.

Your email is never shown publicly.